BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/31/2015 2:38:00 PM | Browse: 665 | Download: 738
Publication Name World Journal of Diabetes
Manuscript ID 10887
Country/Territory Japan
Received
2014-04-24 20:38
Peer-Review Started
2014-04-24 22:35
To Make the First Decision
2014-05-14 13:37
Return for Revision
2014-05-20 20:48
Revised
2014-05-30 14:48
Second Decision
2014-11-21 12:06
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-12-01 13:49
Articles in Press
2014-12-01 13:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-01-15 16:06
Publish the Manuscript Online
2015-01-31 14:38
ISSN 1948-9358 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology and Metabolism
Manuscript Type Review
Article Title Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan
Manuscript Source Invited Manuscript
All Author List Tsuyoshi Ohkura
Funding Agency and Grant Number
Corresponding Author Tsuyoshi Ohkura, MD, PhD, Assistant Professor, Division of Cardiovascular Medicine, Endocrinology and Metabolism, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, 36-1 Nishi-chou, Yonago, Tottori, Japan. ohkura@med.tottori-u.ac.jp
Key Words Sodium-glucose cotransporter 2 inhibitor; Type 2 diabetes mellitus; Ipragliflozin; Japan
Core Tip Ipragliflozin is highly selective for sodium-glucose cotransporter 2 (SGLT2) inhibitor. Twelve weeks of ipragliflozin 50 mg/d vs placebo decreased HbA1c and body weight by 0.65% and 0.66 kg, respectively, in Western patients, and by 1.3% and 1.89 kg, respectively, in Japanese patients. The highly selective SGLT2 inhibitor ipragliflozin improves glycemic control and reduces body weight, and lowers hypoglycemic risk and abdominal symptoms. Ipragliflozin has potential as a novel anti-diabetic and anti-obesity agent.
Publish Date 2015-01-31 14:38
Citation Ohkura T. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes 2015; 6(1): 136-144
Url http://www.wjgnet.com/1948-9358/full/v6/i1/136.htm
DOI http://dx.doi.org/10.4239/wjd.v6.i1.136
Full Article (PDF) WJD-6-1.pdf
Full Article (Word) WJD-6-1.doc
Manuscript File 10887-Review.doc
Answering Reviewers 10887-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form 10887-Conflict-of-interest statement.pdf
Copyright License Agreement 10887-Copyright assignment.pdf
Peer-review Report 10887-Peer review(s).pdf
Scientific Misconduct Check 10887-CrossCheck.jpg
Scientific Editor Work List 10887-Scientific editor work list.pdf